Gilead Sciences Income Statement
GILD / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 15 fiscal years. All figures from audited SEC 10-K filings.
Gilead Sciences reported $29.4B in revenue and $8.5B in net income for FY2025. Revenue has grown at a 9.4% compound annual rate over the past 14 years.
Based on SEC 10-K filings.
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29.4B | $28.8B | $27.3B | $24.7B | $22.4B | $24.7B | $26.1B | $30.4B | $32.6B | $24.9B | $32.6B | $9.7B | $11.2B | $2.3B | $8.4B |
| Cost of Revenue | $6.2B | $6.3B | $6.6B | $4.6B | $4.7B | $4.6B | $4.4B | $4.3B | $4.0B | $3.8B | $4.0B | $2.5B | $2.9B | $2.5B | $2.1B |
| Gross Profit | - | - | - | - | - | - | $4.2B | $4.0B | $5.4B | $6.5B | $6.5B | $4.1B | $1.8B | $1.6B | $1.4B |
| SG&A Expense | $5.8B | $6.1B | $5.2B | $5.2B | $4.4B | $5.2B | $3.9B | $3.4B | $3.4B | $3.0B | $3.4B | $1.5B | $1.7B | $1.5B | $1.2B |
| R&D Expense | $5.8B | $5.9B | $4.6B | $4.9B | $4.1B | $4.9B | $3.7B | $5.1B | $3.0B | $2.9B | $3.0B | $1.8B | $2.1B | $1.8B | $1.2B |
| Operating Income | $10.0B | $1.7B | $9.9B | $4.1B | $4.3B | $4.1B | $14.1B | $17.6B | $22.2B | $15.3B | $22.2B | $4.0B | $4.5B | $4.0B | $3.8B |
| Interest Expense | - | - | $1.0B | $984.0M | $995.0M | $984.0M | $1.1B | $964.0M | $688.0M | $412.0M | $688.0M | $361.0M | $307.0M | $361.0M | $205.4M |
| Income Tax | $1.3B | $211.0M | $2.1B | $1.6B | -$204.0M | $1.6B | $8.9B | $3.6B | $3.6B | $2.8B | $3.6B | $1.0B | $1.2B | $1.0B | $861.9M |
| Net Income | $8.5B | $480.0M | $6.2B | $123.0M | $5.4B | $123.0M | $4.6B | $13.5B | $18.1B | $12.1B | $18.1B | $2.6B | $3.1B | $2.6B | $2.8B |
| EPS (Basic) | $6.84 | $3.66 | $4.96 | $0.10 | $4.24 | $4.20 | $3.54 | $10.08 | $12.37 | $7.95 | $2.01 | $1.71 | $1.81 | $1.69 | $2.91 |
| EPS (Diluted) | $6.78 | $3.64 | $4.93 | $0.10 | $4.22 | $4.17 | $3.51 | $9.94 | $11.91 | $7.35 | $1.81 | $1.64 | $1.77 | $1.66 | $2.82 |
| Shares Outstanding | 1.2B | 1.2B | 1.2B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.4B | 1.5B | 1.5B | 1.5B | 1.5B | 802.0M |
| Gross Margin | - | - | - | - | - | - | 16.3% | 13.2% | 16.6% | 26.1% | 20.0% | 41.8% | 15.7% | 71.3% | 16.6% |
| Operating Margin | 34.0% | 5.8% | 36.3% | 16.5% | 19.1% | 16.5% | 54.1% | 58.0% | 68.0% | 61.3% | 68.0% | 41.3% | 40.4% | 175.7% | 45.2% |
| Profit Margin | 28.9% | 1.7% | 22.8% | 0.5% | 24.0% | 0.5% | 17.7% | 44.4% | 55.5% | 48.6% | 55.5% | 26.7% | 27.5% | 113.6% | 33.4% |